STOCK TITAN

[Form 4] MacroGenics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Scott Koenig, a director of MacroGenics, Inc. (MGNX), reported vested restricted stock units (RSUs) on 08/13/2025 that converted into common stock. The Form 4 shows two separate RSU vesting transactions under code M, totaling 52,829 RSUs (21,165 and 31,664) with a reported price of $0 per unit because each RSU represents a contingent right to one share. The filing states these vestings occurred pursuant to a Separation and Consulting Agreement that caused 50% of each outstanding unvested RSU to vest, and that vested shares will be delivered as soon as practicable. The Form is signed by an attorney-in-fact on 08/15/2025. The reported beneficial ownership figures following the transactions are shown as 798,580 and 830,244 shares on the two reporting lines.

Scott Koenig, direttore di MacroGenics, Inc. (MGNX), ha dichiarato che il 13/08/2025 si sono vestite unità azionarie vincolate (RSU) che si sono convertite in azioni ordinarie. Il Modulo 4 riporta due operazioni separate di vesting di RSU con codice M, per un totale di 52.829 RSU (21.165 e 31.664), con prezzo dichiarato di $0 per unità in quanto ciascuna RSU rappresenta il diritto condizionato a una azione. La documentazione indica che tali vesting sono avvenuti in virtù di un Accordo di Separazione e Consulenza che ha fatto maturare il 50% di ogni RSU non ancora maturata, e che le azioni maturate saranno consegnate non appena possibile. Il modulo è firmato da un procuratore il 15/08/2025. Le quote di proprietà benefica riportate dopo le operazioni sono 798.580 e 830.244 azioni nelle due righe di segnalazione.

Scott Koenig, director de MacroGenics, Inc. (MGNX), informó que el 13/08/2025 se consolidaron unidades restringidas de acciones (RSU) que se convirtieron en acciones ordinarias. El Formulario 4 muestra dos transacciones separadas de consolidación de RSU bajo el código M, por un total de 52.829 RSU (21.165 y 31.664), con un precio declarado de $0 por unidad, ya que cada RSU representa el derecho contingente a una acción. La presentación señala que estos vestings se realizaron conforme a un Acuerdo de Separación y Consultoría que hizo que se consolidara el 50% de cada RSU pendiente, y que las acciones consolidadas se entregarán lo antes posible. El formulario está firmado por un apoderado el 15/08/2025. Las cifras de propiedad beneficiaria reportadas tras las transacciones aparecen como 798.580 y 830.244 acciones en las dos líneas de reporte.

MacroGenics, Inc.(MGNX) 이사인 Scott Koenig은 2025-08-13에 제한부주식단위(RSU)가 성립되어 보통주로 전환되었다고 보고했습니다. Form 4에는 코드 M으로 표시된 두 건의 RSU 성립 거래가 각각 기재되어 있으며 총 52,829 RSU(21,165 및 31,664)로, 각 단위는 주식에 대한 조건부 권리를 의미하므로 단가가 $0로 보고되어 있습니다. 제출서에는 이 성립들이 분리 및 컨설팅 계약(Separation and Consulting Agreement)에 따라 발생해 미성숙 RSU의 50%가 성립되었고, 성립된 주식은 가능한 한 조속히 인도될 것이라고 명시되어 있습니다. 해당 양식은 2025-08-15에 법적 대리인이 서명했습니다. 거래 후 보고된 실소유 지분 수치는 두 신고 라인에 각각 798,580830,244주로 표시되어 있습니다.

Scott Koenig, administrateur de MacroGenics, Inc. (MGNX), a déclaré que des unités d’actions restreintes (RSU) ont acquis le droit (vested) le 13/08/2025 et se sont converties en actions ordinaires. Le formulaire 4 montre deux opérations de vesting distinctes de RSU sous le code M, totalisant 52 829 RSU (21 165 et 31 664), avec un prix déclaré de 0 $ par unité, chaque RSU représentant un droit conditionnel à une action. Le dépôt indique que ces vestings ont eu lieu en vertu d’un accord de séparation et de conseil entraînant la acquisition de 50 % de chaque RSU non acquise, et que les actions acquises seront délivrées dès que possible. Le formulaire est signé par un mandataire le 15/08/2025. Les parts de propriété bénéficiaire déclarées après les opérations sont indiquées 798 580 et 830 244 actions sur les deux lignes de déclaration.

Scott Koenig, Direktor von MacroGenics, Inc. (MGNX), meldete, dass am 13.08.2025 beschränkte Aktieneinheiten (RSUs) vested wurden und in Stammaktien umgewandelt wurden. Das Formular 4 zeigt zwei getrennte RSU-Vesting-Transaktionen unter dem Code M, insgesamt 52.829 RSUs (21.165 und 31.664), mit einem gemeldeten Preis von $0 pro Einheit, da jede RSU ein bedingtes Recht auf eine Aktie darstellt. Die Einreichung gibt an, dass diese Vestings aufgrund einer Trennungs- und Beratungsvereinbarung erfolgten, durch die 50% jeder noch nicht gefestigten RSU vested wurden, und dass die vested Aktien so bald wie möglich geliefert werden. Das Formular wurde am 15.08.2025 von einem Bevollmächtigten unterzeichnet. Die nach den Transaktionen gemeldeten wirtschaftlichen Eigentumszahlen sind auf den beiden Meldezeilen mit 798.580 bzw. 830.244 Aktien angegeben.

Positive
  • Transparent disclosure of accelerated vesting and exact RSU counts (21,165 and 31,664) on Form 4
  • Clear explanation that each RSU represents a contingent right to one share and that vested shares will be delivered
Negative
  • None.

Insights

TL;DR: Director received 52,829 RSUs that vested under a Separation and Consulting Agreement; this is a non-sale vesting event with limited immediate liquidity impact.

The filing documents two vesting events on 08/13/2025 totaling 52,829 RSUs (21,165 and 31,664). Each RSU is a contingent right to one common share and is reported at $0, consistent with RSU accounting where no cash purchase occurred. The trigger is explicit: a Separation and Consulting Agreement accelerated 50% of outstanding unvested RSUs. This increases the director's reported beneficial ownership balance as shown in the filing. This is a disclosure of ownership change rather than a purchase or sale that would alter market supply.

TL;DR: Vesting tied to a Separation and Consulting Agreement suggests a contractual change in relationship; the filing appropriately discloses accelerated RSU vesting and delivery timing.

The Form 4 clearly attributes the accelerated vesting to a Separation and Consulting Agreement and notes vested shares will be delivered as soon as practicable. The report is executed by an attorney-in-fact, indicating proper procedural handling. The disclosure provides material detail about the mechanism of vesting but does not indicate any sale, exercise for cash, or transfer of shares beyond the vesting and forthcoming delivery.

Scott Koenig, direttore di MacroGenics, Inc. (MGNX), ha dichiarato che il 13/08/2025 si sono vestite unità azionarie vincolate (RSU) che si sono convertite in azioni ordinarie. Il Modulo 4 riporta due operazioni separate di vesting di RSU con codice M, per un totale di 52.829 RSU (21.165 e 31.664), con prezzo dichiarato di $0 per unità in quanto ciascuna RSU rappresenta il diritto condizionato a una azione. La documentazione indica che tali vesting sono avvenuti in virtù di un Accordo di Separazione e Consulenza che ha fatto maturare il 50% di ogni RSU non ancora maturata, e che le azioni maturate saranno consegnate non appena possibile. Il modulo è firmato da un procuratore il 15/08/2025. Le quote di proprietà benefica riportate dopo le operazioni sono 798.580 e 830.244 azioni nelle due righe di segnalazione.

Scott Koenig, director de MacroGenics, Inc. (MGNX), informó que el 13/08/2025 se consolidaron unidades restringidas de acciones (RSU) que se convirtieron en acciones ordinarias. El Formulario 4 muestra dos transacciones separadas de consolidación de RSU bajo el código M, por un total de 52.829 RSU (21.165 y 31.664), con un precio declarado de $0 por unidad, ya que cada RSU representa el derecho contingente a una acción. La presentación señala que estos vestings se realizaron conforme a un Acuerdo de Separación y Consultoría que hizo que se consolidara el 50% de cada RSU pendiente, y que las acciones consolidadas se entregarán lo antes posible. El formulario está firmado por un apoderado el 15/08/2025. Las cifras de propiedad beneficiaria reportadas tras las transacciones aparecen como 798.580 y 830.244 acciones en las dos líneas de reporte.

MacroGenics, Inc.(MGNX) 이사인 Scott Koenig은 2025-08-13에 제한부주식단위(RSU)가 성립되어 보통주로 전환되었다고 보고했습니다. Form 4에는 코드 M으로 표시된 두 건의 RSU 성립 거래가 각각 기재되어 있으며 총 52,829 RSU(21,165 및 31,664)로, 각 단위는 주식에 대한 조건부 권리를 의미하므로 단가가 $0로 보고되어 있습니다. 제출서에는 이 성립들이 분리 및 컨설팅 계약(Separation and Consulting Agreement)에 따라 발생해 미성숙 RSU의 50%가 성립되었고, 성립된 주식은 가능한 한 조속히 인도될 것이라고 명시되어 있습니다. 해당 양식은 2025-08-15에 법적 대리인이 서명했습니다. 거래 후 보고된 실소유 지분 수치는 두 신고 라인에 각각 798,580830,244주로 표시되어 있습니다.

Scott Koenig, administrateur de MacroGenics, Inc. (MGNX), a déclaré que des unités d’actions restreintes (RSU) ont acquis le droit (vested) le 13/08/2025 et se sont converties en actions ordinaires. Le formulaire 4 montre deux opérations de vesting distinctes de RSU sous le code M, totalisant 52 829 RSU (21 165 et 31 664), avec un prix déclaré de 0 $ par unité, chaque RSU représentant un droit conditionnel à une action. Le dépôt indique que ces vestings ont eu lieu en vertu d’un accord de séparation et de conseil entraînant la acquisition de 50 % de chaque RSU non acquise, et que les actions acquises seront délivrées dès que possible. Le formulaire est signé par un mandataire le 15/08/2025. Les parts de propriété bénéficiaire déclarées après les opérations sont indiquées 798 580 et 830 244 actions sur les deux lignes de déclaration.

Scott Koenig, Direktor von MacroGenics, Inc. (MGNX), meldete, dass am 13.08.2025 beschränkte Aktieneinheiten (RSUs) vested wurden und in Stammaktien umgewandelt wurden. Das Formular 4 zeigt zwei getrennte RSU-Vesting-Transaktionen unter dem Code M, insgesamt 52.829 RSUs (21.165 und 31.664), mit einem gemeldeten Preis von $0 pro Einheit, da jede RSU ein bedingtes Recht auf eine Aktie darstellt. Die Einreichung gibt an, dass diese Vestings aufgrund einer Trennungs- und Beratungsvereinbarung erfolgten, durch die 50% jeder noch nicht gefestigten RSU vested wurden, und dass die vested Aktien so bald wie möglich geliefert werden. Das Formular wurde am 15.08.2025 von einem Bevollmächtigten unterzeichnet. Die nach den Transaktionen gemeldeten wirtschaftlichen Eigentumszahlen sind auf den beiden Meldezeilen mit 798.580 bzw. 830.244 Aktien angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Koenig Scott

(Last) (First) (Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 M 21,165(1) A $0(2) 798,580 D
Common Stock 08/13/2025 M 31,664(1) A $0(2) 830,244 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0(2) 08/13/2025 M 21,165 (1) (1) Common Stock 21,165 $0 21,165 D
Restricted Stock Unit $0(2) 08/13/2025 M 31,664 (1) (1) Common Stock 31,664 $0 31,663 D
Explanation of Responses:
1. Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting.
2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
Remarks:
/s/ Beth A. Smith, Attorney-in-fact 08/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Scott Koenig report on Form 4 for MGNX?

The Form 4 reports two RSU vesting transactions on 08/13/2025 totaling 52,829 RSUs (21,165 and 31,664) that converted into rights to common stock.

Why did the RSUs vest for the reporting person?

The filing states 50% of each outstanding unvested RSU immediately vested pursuant to a Separation and Consulting Agreement between the company and the reporting person.

How many shares did the reporting person beneficially own after the transactions?

The Form lists beneficial ownership figures following the transactions as 798,580 and 830,244 shares on the two reporting lines.

Was there any cash paid for the RSUs on vesting?

No cash was reported; each RSU is reported with a price of $0 and represents a contingent right to one share of common stock.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact, Beth A. Smith, on 08/15/2025.
Macrogenics Inc

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Latest SEC Filings

MGNX Stock Data

104.73M
57.96M
3.01%
88.71%
6.46%
Biotechnology
Pharmaceutical Preparations
Link
United States
Rockville